<DOC>
	<DOCNO>NCT01278758</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics ASA404 patient refractory relapse metastatic cancer impair renal function normal renal function . It possible patient renal impairment show difference renal excretion parent ASA404 metabolites , warrant study lead well pharmacokinetic assesssment population .</brief_summary>
	<brief_title>A Dose-escalation Pharmacokinetic Study Intravenous ASA404 Adult Advanced Cancer Patients With Impaired Renal Function Patients With Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>Patients histologicallyproven solid tumor , either refractory standard chemotherapy ; Patients chemotherapy investigaional agent combination docetaxel , paclitaxel + carboplatin appropriate ; Creatinine clearance accord CockcroftGault formula : Normal &gt; 80 mL/min , Mild 5080 mL/min , Moderate 30 &lt; 50 mL/min ; A minimum 4 week must elapse since last treatment cancer therapy ; Potassium , calcium , magnesium phosphorus value within normal range ; Body Mass Index ( BMI ) must within range 18 30 Patients CNS metastasis , must CT MRI brain perform rule CNS metastasis ; Patients leptomeningeal disease metastasis ; Radiotherapy &lt; / week prior start study drug ; Major surgery &lt; / 4 week prior start study ; Administration CYP1A2 CYP3A4/5 enzyme induce inhibit drug within 14 day prior start study drug ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced metastatic cancer ,</keyword>
	<keyword>refractory ,</keyword>
	<keyword>core phase ,</keyword>
	<keyword>extension phase ,</keyword>
	<keyword>dose escalation ,</keyword>
	<keyword>standard chemotherapy ,</keyword>
	<keyword>doctaxel ,</keyword>
	<keyword>paclitaxel ,</keyword>
	<keyword>carboplatin ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>tolerability</keyword>
</DOC>